Print page Share page

Iclusig® (ponatinib) and brigatinib (AP26113).

Ponatinib and brigatinib (AP26113) are currently in a number of ARIAD-sponsored clinical trials.

OPTIC (Optimizing Ponatinib Treatment In CML) trial of ponatinib

Patient enrollment has started in the OPTIC (Optimizing Ponatinib Treatment In CML) trial of ponatinib. This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the optimal use of Iclusig in these patients. Approximately 450 patients will be enrolled at clinical sites around the world. Read Full Press Release

Ponatinib in GIST

In June of 2013, we announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The trial is designed to provide initial clinical data evaluating the efficacy and safety of ponatinib in patients with GIST following failure of prior tyrosine kinase inhibitor (TKI) therapy. Read Full Press Release

Phase 1/2 study of ponatinib in Japanese patients with CML and Ph+ ALL

In August 2012, we announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of Iclusig. The trial is being conducted in Japanese patients with chronic myeloid leukemia (CML) who have failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who have failed prior tyrosine kinase inhibitors. Read Full Press Release

Phase 2 ALTA trial of Brigatinib (AP26113)

In March 2014, ARIAD announced the initiation of its pivotal global Phase 2 ALTA (ALK in Lung Cancer Trial of brigatinib (AP26113) in patients with locally advanced or metastatic NSCLC who test positive for the ALK oncogene and were previously treated with crizotinib. This trial has reached full enrollment of approximately 220 patients and explores two different dose levels. Read Full Press Release

Phase 1/2 study of oral ALK inhibitor Brigatinib (AP26113)

In September of 2011, ARIAD announced the start of patient dosing in an international Phase 1/2 clinical trial of brigatinib (AP26113), an investigational inhibitor of anaplastic lymphoma kinase (ALK). Read Full Press Release

ARIAD-sponsored trials

View all open clinical trials at

You are now leaving this website. If you would like to continue, click Continue.